In the United States, by the end of June, women will have access to a new medication for postpartum depression.
The US Drug Administration (FDA) validated Tuesday, March 19, the marketing of a new drug against postpartum depression, a serious mental illness that affects some mothers after giving birth.
Called brexanolone (Zulresso brand, Sage Therapeutics laboratory), the drug works in two days, much faster than traditional antidepressants. But it carries a high risk of fainting, and must therefore be administered intravenously to the hospital, under medical supervision for sixty hours.
To hurt themselves or to hurt their child
"Postpartum depression is a serious condition that, when severe, can be life-threatening, and women may have thoughts about hurting themselves or hurting their child," Tiffany Farchione said in a statement. Acting Director of the Psychiatric Products Division of the FDA's Center for Drug Evaluation.
The treatment should be available from the end of June in the United States, and should cost $ 34,000, plus the price of hospital stay. According to a study by the Centers for Disease Control and Prevention, 11.5% of new mothers had postpartum depression in 2012 in the United States.
The most common symptoms
Postpartum depression is the most common postnatal psychiatric disorder and affects 10 to 15% of French mothers. His diagnosis is based on the criteria of a major depressive episode, with a specific appearance of symptoms within 4 or 6 weeks after delivery. Studies, however, recognize a later onset (up to one year after childbirth).
The most common symptoms are difficulty falling asleep, overactive behavior, difficulty concentrating, irritability, anxiety and permanent fatigue. Disorders of mother-baby interaction can also occur.